Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003070 · ClinicalTrials.gov registry record · Phase 3
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
A Phase 3 study of Unspecified Childhood Solid Tumor, Protocol Specific and Cardiac Toxicity, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
- 20
- Study locations
NCT00003070 is a Phase 3 study of Unspecified Childhood Solid Tumor, Protocol Specific and Cardiac Toxicity that has completed, run by Children's Oncology Group. The registered enrollment target is 13 participants, below the 1,637-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00003070, a Phase 3 study of Unspecified Childhood Solid Tumor, Protocol Specific and Cardiac Toxicity, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy. It is not known whether enalapril is more effective than a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of enalapril with a placebo in treating heart damage in patients who received anthracycline chemotherapy for childhood cancer.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- DRUG enalapril maleate
Study Locations (20)
Florida
- Shands Hospital and Clinics, University of Florida - Gainesville
- Sylvester Cancer Center, University of Miami - Miami
- Miami Children's Hospital - Miami
- CCOP - Florida Pediatric - Tampa
California
- University of California San Diego Cancer Center - La Jolla
- Lucile Packard Children's Hospital at Stanford - Palo Alto
- University of California Davis Medical Center - Sacramento
Louisiana
- MBCCOP - LSU Health Sciences Center - New Orleans
- CCOP - Ochsner - New Orleans
- Ochsner Clinic - New Orleans
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- MBCCOP - Gulf Coast - Mobile
Kansas
- University of Kansas Medical Center - Kansas City
- CCOP - Wichita - Wichita
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Yale Comprehensive Cancer Center - New Haven
District of Columbia
- Walter Reed Army Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2000-09 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003070
The ClinicalTrials.gov registry entry for NCT00003070 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,637-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (99% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00003070 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00003070 about?
NCT00003070 is a clinical study titled "Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy. It is not known whether enalapril is more effective than a placebo in tre...
What is the current status of trial NCT00003070?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2000-09. Estimated completion is 2007-03.
What conditions does trial NCT00003070 study?
This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific, Cardiac Toxicity.
What interventions are being tested in trial NCT00003070?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), enalapril maleate (DRUG).
Who is sponsoring clinical trial NCT00003070?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003070 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Childhood Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
RECRUITING
-
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
COMPLETED · Phase 2
-
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
COMPLETED · Phase 1
-
Telephone-Based Cancer Education With or Without Telephone-Based Counseling in Young Participants
COMPLETED · NA
-
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
COMPLETED · Phase 1
-
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
COMPLETED · NA
Explore more on PlainTrial
Unspecified Childhood Solid Tumor, Protocol Specific
All registered trials for this condition
Cardiac Toxicity
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.